PCRX

23.75

1.29% -0.31

Handel nachbörslich: 23.75

Pacira Biosciences Inc (PCRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$24.06

Offen:

$23.95

24-Stunden-Volumen:

307.06K

Relative Volume:

0.37

Marktkapitalisierung:

$961.63M

Einnahmen:

$726.41M

Nettoeinkommen (Verlust:

$7.03M

KGV:

151.18

EPS:

0.1571

Netto-Cashflow:

$136.66M

1W Leistung:

+5.42%

1M Leistung:

+2.11%

6M Leistung:

+4.49%

1J Leistung:

-4.89%

1-Tages-Spanne:

$23.69

$24.38

1-Wochen-Bereich:

$22.75

$24.38

52-Wochen-Spanne:

$18.80

$27.98

Pacira Biosciences Inc Stock (PCRX) Company Profile

Firmenname

Pacira Biosciences Inc

Sektor

Healthcare (1110)

Branche

Drug Manufacturers - Specialty & Generic (83)

Telefon

650-242-8052

Adresse

2000 SIERRA POINT PARKWAY, BRISBANE, NJ

Mitarbeiter

829

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

PCRX's Discussions on Twitter

Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PCRX Pacira Biosciences Inc	23.75	963.25M	726.41M	7.03M	136.66M	0.1571
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-09	Eingeleitet	Barclays	Equal Weight
2025-11-17	Eingeleitet	H.C. Wainwright	Buy
2025-07-25	Hochstufung	Truist	Hold → Buy
2025-01-30	Hochstufung	Truist	Sell → Hold
2024-08-13	Herabstufung	Truist	Buy → Sell
2024-08-12	Herabstufung	JP Morgan	Overweight → Underweight
2024-08-12	Herabstufung	Piper Sandler	Overweight → Neutral
2024-08-12	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2024-08-12	Herabstufung	Raymond James	Outperform → Mkt Perform
2024-07-03	Herabstufung	Barclays	Overweight → Equal Weight
2024-03-07	Fortgesetzt	JP Morgan	Overweight
2023-12-20	Eingeleitet	Raymond James	Outperform
2023-08-03	Hochstufung	TD Cowen	Market Perform → Outperform
2023-01-31	Fortgesetzt	Wedbush	Outperform
2022-10-21	Fortgesetzt	Jefferies	Buy
2022-01-03	Fortgesetzt	JP Morgan	Overweight
2021-07-26	Hochstufung	JP Morgan	Neutral → Overweight
2021-04-21	Fortgesetzt	JP Morgan	Neutral
2021-04-09	Eingeleitet	Berenberg	Buy
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-02-11	Herabstufung	Northland Capital	Outperform → Market Perform
2021-01-21	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-09-21	Hochstufung	Northland Capital	Market Perform → Outperform
2020-07-06	Bestätigt	Needham	Buy
2020-05-27	Eingeleitet	Guggenheim	Neutral
2020-04-07	Eingeleitet	Northland Capital	Outperform
2020-03-20	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-02-24	Bestätigt	H.C. Wainwright	Buy
2020-01-24	Eingeleitet	SunTrust	Buy
2020-01-23	Eingeleitet	SunTrust	Buy
2019-11-06	Eingeleitet	BTIG Research	Buy
2019-06-11	Eingeleitet	Barclays	Overweight
2019-05-06	Hochstufung	Mizuho	Underperform → Neutral
2019-05-02	Hochstufung	Stifel	Sell → Hold
2019-02-01	Herabstufung	Mizuho	Neutral → Underperform
2018-08-06	Herabstufung	BofA/Merrill	Buy → Neutral
2018-04-09	Bestätigt	H.C. Wainwright	Buy
2018-03-21	Bestätigt	Mizuho	Neutral
2018-02-16	Herabstufung	Needham	Buy → Hold
2018-01-19	Eingeleitet	Seaport Global Securities	Buy
2018-01-04	Bestätigt	Canaccord Genuity	Buy
2018-01-03	Eingeleitet	Leerink Partners	Mkt Perform

Alle ansehen

Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten

Apr 13, 2026

Pacira (PCRX) Data Highlights Cost Benefits and Opioid Reduction - GuruFocus

Apr 13, 2026

Pacira BioSciences, Inc. Presents Real-World Data On EXPAREL Showing Lower Total Healthcare Costs In Outpatient Total Hip And Knee Arthroplasty Procedures - marketscreener.com

Apr 13, 2026

Pacira (PCRX) Highlights Economic Benefits of Exparel in Orthope - GuruFocus

Apr 13, 2026

Hip replacement patients with back pain used fewer opioids with EXPAREL - Stock Titan

Apr 13, 2026

Apr 11, 2026

(PCRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Apr 11, 2026

Apr 10, 2026

Investment Recap: Can Pacira BioSciences Inc expand its profit marginsWeekly Trade Report & Risk Controlled Daily Plans - baoquankhu1.vn

Apr 10, 2026

PCRX.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Apr 10, 2026

Weekly Earnings: Is Pacira BioSciences Inc stock a falling knife or bargain buy2026 Outlook & Risk Managed Investment Strategies - baoquankhu1.vn

Apr 10, 2026

PCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 10, 2026

Apr 09, 2026

Dimensional Fund Advisors (NASDAQ: PCRX) reports 2.06M shares owned - Stock Titan

Apr 09, 2026

Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 08, 2026

Pacira investors get live access to Needham healthcare event April 15 - Stock Titan

Apr 08, 2026

Apr 07, 2026

Pacira (PCRX) BioSciences well-positioned with genicular outcomes registry evidence - MSN

Apr 07, 2026

Apr 05, 2026

2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse

Apr 05, 2026

Apr 04, 2026

PCRX Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 03, 2026

PCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 03, 2026

Apr 02, 2026

2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse

Apr 02, 2026